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Abstract
Introduction Allogeneic hematopoietic cell transplantation
(HCT) was a standard therapy in chronic phase (CP) chronic
myeloid leukemia (CML). As a result of the effective therapy
with tyrosine kinase inhibitors (TKI), HCT was shifted to
defined clinical situations. We present the results of observa-
tional prospective analysis of 28 CML patients undergoing
HCT after exposure to, at least, two lines of TKI (including
dasatinib and/or nilotinib), with respect to response, overall
survival (OS), treatment toxicity, graft versus host disease
(GVHD), and progression/relapse incidence.
Results All the patients but one engrafted with median time
19 days. OS for patients in CP1 and CP2/accelerated phase
(AcP) were 92.9 and 85.7 %, respectively. Six patients
allotransplanted in blast crisis (BC) CML died early after
HCT.
Eighteen patients achieved deep molecular remission
(MR4.5 or MR4.0). Relapse incidence was 29.6 %. Median
time to progression (TTP) differs significantly depending on
the CML phase prior to HCT, the best response achieved after
HCT and development of chronic GvHD.
NRM yielded the values 7.1, 12.5, and 50 % in CP1, CP2/
AcP, and BC, respectively. Fatal outcome, due to veno-
occlusive disease (VOD), was observed in two (7 %) patients.
In five (17.9 %) patients, mild or moderate VOD was ob-
served with no negative impact of preceding therapy with
TKI2. Acute GvHD was diagnosed in 25.9 % of patients,
while chronic GvHD developed in 42.9 % of individuals.
Conclusion Pretransplantation therapy with TKI2 in CP CML
is safe and reasonable. In BC, the optimal approach before
HCT is to reduce the leukemic burden and achieve subsequent
CP.
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Introduction
Allogeneic hematopoietic cell transplantation (HCT) was his-
torically a standard curative therapy for patients with chronic
phase (CP) chronic myeloid leukemia (CML). As a result of
the novel highly effective therapy with tyrosine kinase inhib-
itors (TKI), the use of HCT was shifted to defined clinical
situations. Following the European LeukemiaNet (ELN)
guidelines, patients with Philadelphia positive (Ph+) CML
diagnosed in the advanced phase (accelerated phase (AcP);
blast phase/crisis (BC)) or resistant to imatinib or second-
generation TKI (TKI2), should be qualified to HCT [1]. A
number of published data shows no serious negative impact
of imatinib mesylate therapy prior to HCT [2–5], but only few
studies concerning the outcome of HCT in TKI2-resistant pa-
tients are currently available [6].
Non-relapse mortality (NRM) and organ toxicity in pa-
tients receiving TKI2 before transplantation are of interest.
Based on the toxicity profile of both dasatinib and nilotinib,
development of hepatic veno-occlusive disease (VOD),
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cardiac toxicity, as well as immune dysfunctions or delayed
engraftment can be expected [7, 8]. The long term outcome of
TKI2-resistant patients remains another important issue.
Potentially poorer outcome of patients pre-treated with TKI2
may result from the selection of more aggressive clones of
malignant cells with additional molecular aberrations, promot-
ing their proliferation and survival abilities. Moreover, TKI2-
resistant patients are usually transplanted in more advanced
phases of the disease or are simply older, when they finally
enter the procedure of HCT. Additional problems are related
to the late toxicity of HCT and chronic GvHD, significantly
affecting the quality of life.
In this study, we present the results of observational pro-
spective analysis of CML patients undergoing allogeneic he-
matopoietic cell transplantation after exposure to TKI2, as the
second-line therapy, with respect to response, overall survival,
treatment toxicity, GVHD and progression/relapse incidence.
Patients and methods
Patients
The eligible subjects were patients undergoing allogeneic he-
matopoietic cell transplantation with CML diagnosis, after
pretreatment with imatinib mesylate and one or more TKI2.
The therapy with TKI2 was discontinued at least 2 days prior
to the conditioning regimen. Treatment was provided in two
transplant centers, between February 2008 and November
2013.
The study was approved by the Bioethical Committee of
Medical University of Gdansk and was conducted in accor-
dance with the Declaration of Helsinki.
Definitions
Chronic phase CML was diagnosed according to ELN criteria
when blasts in peripheral blood (PB) and bone marrow (BM)
were <15%, basophilia did not exceed 20%, and there was no
evidence of extramedullary involvement. Accelerated phase
was defined by blasts between 15 and 29 %, basophilia ex-
ceeding 20 %, persistent thrombocytopenia (<100 G/l, not
related to the treatment) or thrombocytosis unresponsive to
the therapy or any cytogenetic evidence of clonal evolution.
Blast phase/crisis was diagnosed when there were 30 % or
more PB or BM blasts, or the extramedullary blast prolifera-
tion occurred.
Molecular monitoring was performed according to the
ELN guidelines with the RQ-PCR method [9–11]. Deep
molecular response MR4.5 was defined as a 4.5-log re-
duction from the baseline (≤0.0032 % BCR-ABL [IS])
or a disease undetectable in complementary DNA
(cDNA) with the amount of the transcript ABL
≥32.000. Deep MR4.0 was defined as a 4-log reduction
from the baseline (≤0.01 % BCR-ABL [IS]) or a dis-
ease, which was undetectable in cDNA with the amount
of the transcript ABL ≥10.000. Major molecular re-
sponse (MMR) was determined when there was a 3-
log reduction from the baseline (≤0.1 % BCR-ABL
[IS]). Minor molecular response (MiMR) was the re-
sponse below MMR.
Progression/relapse of CML after HCT was defined
by any hematologic, cytogenetic, or molecular evidence
of the disease, requiring the additional treatment after
HCT (e.g., TKI re-administration and/or donor lympho-
cyte infusion (DLI)).
Engraftment was achieved when an absolute neutrophil
count was greater or equal to 0.5 G/l, and it was the first of
three consecutive days with this value.
Acute graft versus host disease (GvHD) was diagnosed
according to IBMTR criteria [12, 13]. The diagnosis of chron-
ic GvHD was based on NIH consensus criteria [14].
Hepatic veno-occlusive disease (VOD) was diagnosedwith
occurrence of at least two modified Seattle criteria:
hyperbilirubinemia (>2 mg/dl), hepatomegaly with right up-
per quadrant abdominal pain, and >2 % weight gain due to
fluid retention [15].
NRM was defined as any case of death without symptoms
of relapse.
Statistical analysis
Differences in median values between groups were analyzed
with the Mann-Whitney U test. Correlations were analyzed
using the Spearman’s rank test. Stratified Kaplan-Meier
curves were applied to evaluate association between pa-
tient characteristics and the outcomes. Log-rank test was
used to compare the curves. Since for most of the var-
iables the median survival was not achieved, we report-
ed the mean survival time restricted to the longest
follow-up time. For most of the variables, the largest
observed analysis time was censored and underestima-
tion of the restricted mean survival time was expected.
Multivariate analysis was performed using the Cox re-
gression. P values <0.05 were considered statistically
significant. Calculations were performed using the
Stata 13.1 statistical software (StataCorp, TX, USA).
Results
We prospectively analyzed the data of 28 patients treated with
the second generation TKI (dasatinib, nilotinib, or both in
sequence) before HCT. None of the studied patients, including
those with BC, received conventional chemotherapy prior to
HCT. Their characteristics are presented in Table 1. Patients
were followed-up up to February 2014.
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Engraftment
All the patients, except for one in BC, engrafted with median
time 19 days (13–43 days). The duration of TKI2
therapy prior to HCT had no impact on the time of en-
graftment (p=0.41).
Response
Eighteen patients achieved MR4.5 or MR4.0 with median time
1.8 months after HCT, and this response was maintained in 14
alive patients. Five patients achieved MMR, as the best mo-
lecular response, with median time 1.1 months after HCT, and
this group included one patient in early post-transplant period,
one who died due to aGvHD and three patients who lost this
response. Four patients achieved responses below MMR
(MiMR) and all of them died, due to relapse or aGvHD.
The data concerning the time to achieve the best molecular
response were available for 27 patients. The median value was
1.8 months after HCT and did not depend on patients’ gender
(p=0.4), age (p=0.98), type of a donor (p=0.23), and the
source of hematopoietic cells (p=0.25). Median time to
achieve the best molecular response was the shortest for pa-
tients in CP1 (1.1 months) and the longest in BCCML at HCT
(2.4 months) but the trend was not statistically significant
(p=0.35). The best molecular response was not influenced
by aGvHD occurrence (p=0.52) or cGvHD development
(p=0.96).
Survival
During median 19 months (3–66) of follow-up, 19 patients
survived. Deaths were related to VOD, aGvHD and relapse.
Since all the deaths occurred within the first year after HCT,
the 1- and 3-year observed survival rates were identical and
yielded a value of 71.4 %. OS did not depend on patients’
gender (p=0.97), age (p=0.11), type of a donor (p=0.97),
and the source of hematopoietic cells (p=0.83) but was
strongly influenced by the CML phase prior to HCT
(p=0.0001), Fig. 1.
Crude OS estimates significantly depended on the best mo-
lecular response achieved after HCT; however, the result was
confounded by the CML phase at HCT. After adjustment for
the confounder, patients with deep MR had better prognosis,
but the effect was not statistically significant (HR=0.1;
p=0.08).
Kaplan-Meier estimates of OS for patients in CP1 and CP2/
AcP were 92.9 and 85.7 %, respectively. In the group of 14
patients with CP1 one patient died due to acute GvHD (grade
IV). Among eight patients with more advanced phase (CP2 or
Ac): one died because of aGvHD (grade IV) and one
allotransplanted from the family donor relapsed early in BC
CML.
Six patients were allotransplanted in BC. All of them died
in the early post-transplant period: three due to relapse, one as
a result of fatal acute GvHD, one because of VOD and one due
to multiorgan failure (MOF)/VOD.





Median age at HCT (range) 48 (29–68)




Disease phase at diagnosis, no. (%)
Chronic phase (CP) 20 (72)
Accelerated phase 4 (14)
Blast phase (crisis) 4 (14)
Disease phase at TKI2 treatment, no. (%)
Chronic phase 20 (72)
Accelerated phase 2 (7)
Blast phase (crisis) 6 (21)
Disease phase prior to HCT, no. (%)
First chronic phase (CP1) 14 (50)
Accelerated phase or second CP (CP2) 8 (29)
Blast phase (crisis) 6 (21)
TKI2 therapy duration prior to HCT
Median month (range) 14 (2–60)
≥12 months, no. (%) 13 (46)
<12 months, no. (%) 15 (54)
Donor type, no. (%)
HLA-identical sibling 10 (36)
Matched unrelated 18 (64)
Conditioning regimen, no. (%)
MAC (BuCy; TBICy) 15 (54)
RIC (FluMel; FluBu) 13 (46)
Graft type, no. (%)
PBSC 24 (86)
BM 4 (14)






HCT hematopoietic cell transplantation, TKI2 second-generation tyrosine
kinase inhibitors, MAC myeloablative conditioning, RIC reduced-
intensity conditioning, PBSC peripheral blood stem cells, BM bone
marrow, MTX methotrexate (days +1,+3, +6, +11), CsA cyclosporin,
ATG antithymocyte globulin
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Time to progression
Median time to progression (TTP) in the whole study group
has not been achieved yet, while the mean time has reached
45 months. Median TTP in the group of patients, who lost
their molecular response was 5 months.
TTP did not depend on patients’ gender (p=0.63), age
(p=0.98), type of a donor (p=0.22), the source of hematopoi-
etic cells (p=0.55), and occurrence of aGvHD (p=0.55) but
differs significantly depending on CML phase prior to HCT
(p=0.046), Fig. 2a. TTP also differs depending on the level of
response achieved after HCT (p=0.009), Fig. 2b. Moreover,
TTP was significantly influenced by the development of
cGvHD (p=0.038), Fig. 2c.
Relapse incidence
Relapse after HCT was seen in eight patients (29.6 %). The
incidence of relapse in CP1, CP2/Ac, and BC was 21.4, 12.5,
and 50 %, respectively. Altogether, three molecular relapses
and five hematological relapses were diagnosed.
Hematological relapse was a direct cause of death in three
cases. Those patients were in BC prior to transplantation and
had achieved at most MMR after HCT. Among the remaining
four relapsed patients, three were transplanted in CP1 and one
in CP2. All four patients received RIC prior to HCT. They
were qualified to DLI-based therapy: three due to molecular
relapses and one due to hematological relapse (combined
treatment with DLI and dasatinib). In all of them deep MR
is maintained until the end of follow-up.
Treatment toxicity and GVHD
Total incidence of VOD was 25 % (seven patients) in the
study group. Fatal outcome due to severe transplant-related
toxicity was seen in two (7.1 %) patients, both in BC: hepatic
VOD and MOF/VOD. In five (17.9 %) patients, mild or mod-
erate VOD was observed with complete recovery after con-
ventional treatment, including two patients in BC and three






















Fig. 1 Impact of CML phase on overall survival (OS) after HCT. CP1
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Fig. 2 a–c Impact of clinical
factors on the incidence of
relapse. Cumulative rates of
relapses were estimated according
to the competing risk method.
Non-relapse mortality was
evaluated as a competing risk. CP
chronic phase, Ac accelerated
phase, BC blast crisis/phase,CMR
complete molecular response,
MMR major molecular response,
MiMR minor molecular response
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in BC and CP1/CP2/Ac phase was 66.7 and 13.6 %, respec-
tively. A prolonged therapy with TKI2 had no influence on
VOD occurrence. Incidence of VOD development decreased
along with the duration of TKI2 treatment (p=0.019).
Acute graft versus host disease (aGvHD) was diagnosed in
7 out of 27 patients (25.9 %) including grades I–II in four
patients (11 %). It was established in one (3.7 %) patient in
CP1, three (11.1 %) patients in CP2/Ac, and three (11.1 %)
patients in BCCML.Median survival of patients with aGvHD
grade IV was 3 months.
Among 21 patients with the follow-up period exceeding
100 days after HCT, chronic GvHD (cGvHD) developed in
nine (42.9 %) patients, including one person with cGvHD
induced by DLI. In five (21 %) mild and in four cases, mod-
erate cGvHD was observed. Chronic GvHD had no impact on
OS (p=0.18).
NRM reached 7.1 % for CP1, 12.5 % for CP2/AcP, and
50 % for BC and included deaths caused by VOD/MOF and
GvHD-related complications.
Discussion
The therapy with tyrosine kinase inhibitors has been a stan-
dard care for patients with CML for more than one decade;
that is why data concerning the results of HCT performed
nowadays in TKI-naive individuals are no longer available.
Due to the advance in post-transplant care, our results cannot
be compared reliably to a historical group, prior to the era of
TKI, but might be compared to the published data concerning
the imatinib-pretreated group of patients. The concept to com-
pare data comes from the similarities in the toxicity profile of
imatinib and TKI2.
The clinically important finding of our research is a lack of
severe hepatic VOD and engraftment failure that could poten-
tially complicate the use of second-generation TKI prior to
HCT in a group of patients in early (CP1) or advanced (CP2
and AcP) phase of CML. The therapy with dasatinib or
nilotinib in our study has been discontinued before the condi-
tioning regimen started, the same as imatinib in published
studies. Zaucha et al. [5] presented the results of transplanta-
tion in the group of 30 patients receiving imatinib prior to
HCT, including 26 patients with CML. The group character-
istics differ with the older median age (48 vs 32 years), a
smaller number of patients transplanted fromBM and a higher
proportion of patients in BC CML in our study group. Graft
failure was reported in two patients in the imatinib group and
in one patient in the TKI2 group, while median time to en-
graftment after PBSCT was comparable in both groups. To
confront hepatotoxicity, 23% of patients in the imatinib group
experienced severe hyperbilirubinemia including 10 % who
met VOD criteria, while in our TKI2 group, 25 % developed
VOD, including 7.1 % with fatal outcome, however observed
in patients with BC CML. Patients in CP1/CP2 in our study
had VOD incidence about 14 %, that is comparable to cumu-
lative incidence of VOD recently reported as about 13.8 %
using Seattle criteria [16], and there was no VOD/MOF-
related death in this group. Moreover, a prolonged TKI2 ther-
apy, reducing the leukemia burden, was associated with lower
incidence of hepatic toxicity. Therefore, the strategy to con-
tinue TKI2 treatment as long as it is necessary to find a donor
is a reasonable tactic and TKI2 tapering few days prior to
conditioning appears to be the safe approach.
In contrast to transplantation performed in CP1, CP2, or
AcP phase, BC CML increases significantly the risk of severe
complications and relapse after HCT, which is in line with
data reported by other authors [17, 18]. It is essential to reduce
the load of leukemic cells by TKI and/or chemotherapy to the
level of the second or subsequent CP to achieve the long-
lasting remission. In contrast to high relapse rate in patients
in BC, among seven patients transplanted in CP2 only one
patient died due to relapse, one had molecular relapse success-
fully treated with DLI, and one died due to aGvHD grade IVin
deepMR.With this thesis, we suggest not to postpone HCT in
case of hematological response to TKI2 while waiting for the
deeper molecular response and risking the clonal progression.
Moreover, patients with BC at HCT should be attentively and
frequently monitored after transplantation with the use of the
most sensitive PCR-based tests to detect molecular progres-
sion or relapse. In this high-risk group of patients, the use of
DLI with re-introduction of TKI, may prevent the disease
progression and improve the outcome. It is well known that
patients with relapse detected on the molecular level respond
to DLI with higher remission rate compared to any more ad-
vanced disease [19, 20].
We also analyzed the incidence of acute and chronic GvHD
since the immunomodulatory potency of TKI may determine
the incidence and severity of GvHD. In case of imatinib, the
suggested mechanism of immunosuppression is probably re-
lated to inhibition of T cell activation and dendritic cell devel-
opment [21]. Similar data concerning nilotinib, but mainly
based on in vitro studies, have been reported [22]. The effica-
cy but also toxicity profile of dasatinib is correlated with im-
munomodulatory activity related to the induction of monoclo-
nal T/NK cell proliferation [23]. It is explained by a broad
spectrum of inhibited kinases, including SCR-kinase.
Dasatinib has also an ability to block T cell activity, prolifer-
ation, secretion, and TCR-signaling pathway [24–26]. The
significance of these clonal lymphocytes in anti-leukemic sur-
veillance and their ability to influence graft versus leukemia
and GvHD have not been determined. In our TKI2 study
group, the incidence of aGvHD was 25.9 % including
14.9 % in grade III-IV and was lower than that reported by
Zaucha et al. [5].
Clinically important are encouraging results of survival and
response after HCT achieved in patients with failure of TKI2
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therapy. OS for 22 patients in CP1 and CP2/AcP were 92.9
and 85.7 %, respectively. Among them 18 patients achieved
MR4.5 or MR4.0 with median time 1.8 months after HCT, and
this response has been maintained in 14 alive patients. In four
patients with relapse, deep MR was restored by DLI with/
without TKI support. This confirms the important role of
HCT in CML management.
We conclude that in the view of the curative potential of
HCTand non-inferior survival of patients in CP CMLwith the
pretransplantation TKI2 therapy, compared to the imatinib
therapy, it is a safe and reasonable approach. Nonetheless,
further studies are warranted to assess the individual influence
of nilotinib and dasatinib on the transplant-related toxicity and
the outcome of HCT. In blast crisis, the optimal approach
before HCT is to reduce the leukemic burden. Achievement
of subsequent CP seems to be sufficient to improve the out-
come in this group of patients.
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